Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study

Fadi J Sawaya; Marcus-André Deutsch; Moritz Seiffert; Sung-Han Yoon; Pablo Codner; Upul Wickramarachchi; Azeem Latib; A Sonia Petronio; Josep Rodés-Cabau; Maurizio Taramasso; Marco Spaziano; Johan Bosmans; Luigi Biasco; Darren Mylotte; Mikko Savontaus; Peter Gheeraert; Jason Chan; Troels H Jørgensen; Horst Sievert; Marco Mocetti; Thierry Lefèvre; Francesco Maisano; Antonio Mangieri; David Hildick-Smith; Ran Kornowski; Raj Makkar; Sabine Bleiziffer; Lars Søndergaard; Ole De Backer

doi:10.1016/j.jcin.2017.03.004

Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study

Fadi J Sawaya, Marcus-André Deutsch, Moritz Seiffert, Sung-Han Yoon, Pablo Codner, Upul Wickramarachchi, Azeem Latib, A Sonia Petronio, Josep Rodés-Cabau, Maurizio Taramasso, Marco Spaziano, Johan Bosmans, Luigi Biasco, Darren Mylotte, Mikko Savontaus, Peter Gheeraert, Jason Chan, Troels H Jørgensen, Horst Sievert, Marco MocettiThierry Lefèvre, Francesco Maisano, Antonio Mangieri, David Hildick-Smith, Ran Kornowski, Raj Makkar, Sabine Bleiziffer, Lars Søndergaard, Ole De Backer

163 Citationer (Scopus)

Abstract

OBJECTIVES: The aim of this study was to evaluate the use of transcatheter heart valves (THV) for the treatment of noncalcific pure native aortic valve regurgitation (NAVR) and failing bioprosthetic surgical heart valves (SHVs) with pure severe aortic regurgitation (AR).

BACKGROUND: Limited data are available about the "off-label" use of transcatheter aortic valve replacement (TAVR) to treat pure severe AR.

METHODS: The study population consisted of patients with pure severe AR treated by TAVR at 18 different centers. Study endpoints were device success, early safety, and clinical efficacy at 30 days, as defined by Valve Academic Research Consortium 2 criteria.

RESULTS: A total of 146 patients were included, 78 patients in the NAVR group and 68 patients in the failing SHV group. In the NAVR group, device success, early safety, and clinical efficacy were 72%, 66%, and 61%, respectively. Device success and clinical efficacy were significantly better with newer generation THVs compared with old-generation THVs (85% vs. 54% and 75% vs. 46%, respectively, p < 0.05); this was mainly due to less second THV implantations and a lower rate of moderate to severe paravalvular regurgitation (10% vs. 24% and 3% vs. 27%, respectively). Independent predictors of 30-day mortality were body mass index <20 kg/m2, STS surgical risk score >8%, major vascular or access complication, and moderate to severe AR. In the failing SHV group, device success, early safety, and clinical efficacy were 71%, 90%, and 77%, respectively.

CONCLUSIONS: TAVR for pure NAVR remains a challenging condition, with old-generation THVs being associated with THV embolization and migration and significant paravalvular regurgitation. Newer generation THVs show more promising outcomes. For those patients with severe AR due to failing SHVs, TAVR is a valuable therapeutic option.

Originalsprog	Engelsk
Tidsskrift	JACC: Cardiovascular Interventions
Vol/bind	10
Udgave nummer	10
Sider (fra-til)	1048-1056
Antal sider	9
ISSN	1936-8798
DOI	https://doi.org/10.1016/j.jcin.2017.03.004
Status	Udgivet - 22 maj 2017

Adgang til dokumentet

10.1016/j.jcin.2017.03.004

Citationsformater

Sawaya, F. J., Deutsch, M.-A., Seiffert, M., Yoon, S.-H., Codner, P., Wickramarachchi, U., Latib, A., Petronio, A. S., Rodés-Cabau, J., Taramasso, M., Spaziano, M., Bosmans, J., Biasco, L., Mylotte, D., Savontaus, M., Gheeraert, P., Chan, J., Jørgensen, T. H., Sievert, H., ... De Backer, O. (2017). Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study. JACC: Cardiovascular Interventions, 10(10), 1048-1056. https://doi.org/10.1016/j.jcin.2017.03.004

Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study. / Sawaya, Fadi J; Deutsch, Marcus-André; Seiffert, Moritz et al.
I: JACC: Cardiovascular Interventions, Bind 10, Nr. 10, 22.05.2017, s. 1048-1056.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Sawaya, FJ, Deutsch, M-A, Seiffert, M, Yoon, S-H, Codner, P, Wickramarachchi, U, Latib, A, Petronio, AS, Rodés-Cabau, J, Taramasso, M, Spaziano, M, Bosmans, J, Biasco, L, Mylotte, D, Savontaus, M, Gheeraert, P, Chan, J, Jørgensen, TH, Sievert, H, Mocetti, M, Lefèvre, T, Maisano, F, Mangieri, A, Hildick-Smith, D, Kornowski, R, Makkar, R, Bleiziffer, S, Søndergaard, L & De Backer, O 2017, 'Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study', JACC: Cardiovascular Interventions, bind 10, nr. 10, s. 1048-1056. https://doi.org/10.1016/j.jcin.2017.03.004

Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U et al. Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study. JACC: Cardiovascular Interventions. 2017 maj 22;10(10):1048-1056. doi: 10.1016/j.jcin.2017.03.004

@article{f2d29dc6f2b04d1994a1ec4c55986e69,

title = "Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study",

abstract = "OBJECTIVES: The aim of this study was to evaluate the use of transcatheter heart valves (THV) for the treatment of noncalcific pure native aortic valve regurgitation (NAVR) and failing bioprosthetic surgical heart valves (SHVs) with pure severe aortic regurgitation (AR).BACKGROUND: Limited data are available about the {"}off-label{"} use of transcatheter aortic valve replacement (TAVR) to treat pure severe AR.METHODS: The study population consisted of patients with pure severe AR treated by TAVR at 18 different centers. Study endpoints were device success, early safety, and clinical efficacy at 30 days, as defined by Valve Academic Research Consortium 2 criteria.RESULTS: A total of 146 patients were included, 78 patients in the NAVR group and 68 patients in the failing SHV group. In the NAVR group, device success, early safety, and clinical efficacy were 72%, 66%, and 61%, respectively. Device success and clinical efficacy were significantly better with newer generation THVs compared with old-generation THVs (85% vs. 54% and 75% vs. 46%, respectively, p < 0.05); this was mainly due to less second THV implantations and a lower rate of moderate to severe paravalvular regurgitation (10% vs. 24% and 3% vs. 27%, respectively). Independent predictors of 30-day mortality were body mass index <20 kg/m2, STS surgical risk score >8%, major vascular or access complication, and moderate to severe AR. In the failing SHV group, device success, early safety, and clinical efficacy were 71%, 90%, and 77%, respectively.CONCLUSIONS: TAVR for pure NAVR remains a challenging condition, with old-generation THVs being associated with THV embolization and migration and significant paravalvular regurgitation. Newer generation THVs show more promising outcomes. For those patients with severe AR due to failing SHVs, TAVR is a valuable therapeutic option.",

keywords = "Aged, Aged, 80 and over, Aortic Valve, Aortic Valve Insufficiency, Bioprosthesis, Coronary Angiography, Echocardiography, Female, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Humans, Male, Middle Aged, Prosthesis Failure, Registries, Risk Factors, Time Factors, Transcatheter Aortic Valve Replacement, Treatment Outcome, Journal Article, Multicenter Study, Observational Study",

author = "Sawaya, {Fadi J} and Marcus-Andr{\'e} Deutsch and Moritz Seiffert and Sung-Han Yoon and Pablo Codner and Upul Wickramarachchi and Azeem Latib and Petronio, {A Sonia} and Josep Rod{\'e}s-Cabau and Maurizio Taramasso and Marco Spaziano and Johan Bosmans and Luigi Biasco and Darren Mylotte and Mikko Savontaus and Peter Gheeraert and Jason Chan and J{\o}rgensen, {Troels H} and Horst Sievert and Marco Mocetti and Thierry Lef{\`e}vre and Francesco Maisano and Antonio Mangieri and David Hildick-Smith and Ran Kornowski and Raj Makkar and Sabine Bleiziffer and Lars S{\o}ndergaard and {De Backer}, Ole",

year = "2017",

month = may,

day = "22",

doi = "10.1016/j.jcin.2017.03.004",

language = "English",

volume = "10",

pages = "1048--1056",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses

T2 - Results From an International Registry Study

AU - Sawaya, Fadi J

AU - Deutsch, Marcus-André

AU - Seiffert, Moritz

AU - Yoon, Sung-Han

AU - Codner, Pablo

AU - Wickramarachchi, Upul

AU - Latib, Azeem

AU - Petronio, A Sonia

AU - Rodés-Cabau, Josep

AU - Taramasso, Maurizio

AU - Spaziano, Marco

AU - Bosmans, Johan

AU - Biasco, Luigi

AU - Mylotte, Darren

AU - Savontaus, Mikko

AU - Gheeraert, Peter

AU - Chan, Jason

AU - Jørgensen, Troels H

AU - Sievert, Horst

AU - Mocetti, Marco

AU - Lefèvre, Thierry

AU - Maisano, Francesco

AU - Mangieri, Antonio

AU - Hildick-Smith, David

AU - Kornowski, Ran

AU - Makkar, Raj

AU - Bleiziffer, Sabine

AU - Søndergaard, Lars

AU - De Backer, Ole

PY - 2017/5/22

Y1 - 2017/5/22

N2 - OBJECTIVES: The aim of this study was to evaluate the use of transcatheter heart valves (THV) for the treatment of noncalcific pure native aortic valve regurgitation (NAVR) and failing bioprosthetic surgical heart valves (SHVs) with pure severe aortic regurgitation (AR).BACKGROUND: Limited data are available about the "off-label" use of transcatheter aortic valve replacement (TAVR) to treat pure severe AR.METHODS: The study population consisted of patients with pure severe AR treated by TAVR at 18 different centers. Study endpoints were device success, early safety, and clinical efficacy at 30 days, as defined by Valve Academic Research Consortium 2 criteria.RESULTS: A total of 146 patients were included, 78 patients in the NAVR group and 68 patients in the failing SHV group. In the NAVR group, device success, early safety, and clinical efficacy were 72%, 66%, and 61%, respectively. Device success and clinical efficacy were significantly better with newer generation THVs compared with old-generation THVs (85% vs. 54% and 75% vs. 46%, respectively, p < 0.05); this was mainly due to less second THV implantations and a lower rate of moderate to severe paravalvular regurgitation (10% vs. 24% and 3% vs. 27%, respectively). Independent predictors of 30-day mortality were body mass index <20 kg/m2, STS surgical risk score >8%, major vascular or access complication, and moderate to severe AR. In the failing SHV group, device success, early safety, and clinical efficacy were 71%, 90%, and 77%, respectively.CONCLUSIONS: TAVR for pure NAVR remains a challenging condition, with old-generation THVs being associated with THV embolization and migration and significant paravalvular regurgitation. Newer generation THVs show more promising outcomes. For those patients with severe AR due to failing SHVs, TAVR is a valuable therapeutic option.

AB - OBJECTIVES: The aim of this study was to evaluate the use of transcatheter heart valves (THV) for the treatment of noncalcific pure native aortic valve regurgitation (NAVR) and failing bioprosthetic surgical heart valves (SHVs) with pure severe aortic regurgitation (AR).BACKGROUND: Limited data are available about the "off-label" use of transcatheter aortic valve replacement (TAVR) to treat pure severe AR.METHODS: The study population consisted of patients with pure severe AR treated by TAVR at 18 different centers. Study endpoints were device success, early safety, and clinical efficacy at 30 days, as defined by Valve Academic Research Consortium 2 criteria.RESULTS: A total of 146 patients were included, 78 patients in the NAVR group and 68 patients in the failing SHV group. In the NAVR group, device success, early safety, and clinical efficacy were 72%, 66%, and 61%, respectively. Device success and clinical efficacy were significantly better with newer generation THVs compared with old-generation THVs (85% vs. 54% and 75% vs. 46%, respectively, p < 0.05); this was mainly due to less second THV implantations and a lower rate of moderate to severe paravalvular regurgitation (10% vs. 24% and 3% vs. 27%, respectively). Independent predictors of 30-day mortality were body mass index <20 kg/m2, STS surgical risk score >8%, major vascular or access complication, and moderate to severe AR. In the failing SHV group, device success, early safety, and clinical efficacy were 71%, 90%, and 77%, respectively.CONCLUSIONS: TAVR for pure NAVR remains a challenging condition, with old-generation THVs being associated with THV embolization and migration and significant paravalvular regurgitation. Newer generation THVs show more promising outcomes. For those patients with severe AR due to failing SHVs, TAVR is a valuable therapeutic option.

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve

KW - Aortic Valve Insufficiency

KW - Bioprosthesis

KW - Coronary Angiography

KW - Echocardiography

KW - Female

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation

KW - Humans

KW - Male

KW - Middle Aged

KW - Prosthesis Failure

KW - Registries

KW - Risk Factors

KW - Time Factors

KW - Transcatheter Aortic Valve Replacement

KW - Treatment Outcome

KW - Journal Article

KW - Multicenter Study

KW - Observational Study

U2 - 10.1016/j.jcin.2017.03.004

DO - 10.1016/j.jcin.2017.03.004

M3 - Journal article

C2 - 28521923

SN - 1936-8798

VL - 10

SP - 1048

EP - 1056

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 10

ER -

Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater